Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer

CONCLUSION: HIVEC resulted in a 2-year HG-RFS of 35% for BCG-unresponsive NMIBC patients without severe side-effects and therefore HIVEC seems to be an alternative treatment option for patients who refuse or are unfit for RC.PMID:34470725 | DOI:10.1016/j.urolonc.2021.07.019

Source: Urologic Oncology - September 2, 2021 Category: Urology & Nephrology Authors: Olga M Pijpers Kees Hendricksen Hugh Mostafid Florus C de Jong Marloes Rosier Nikhil Mayor Joep J de Jong Joost L Boormans Source Type: research